PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

Description: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

Summary

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Highlights

Key Questions Answered

- What environmental factors limit the uptake of current HPV vaccines?
- What opportunities exist to overcome these environmental factors?
- What are the main unmet needs of current HPV vaccines?
- What technologies are positioned to address these unmet needs?
- What opportunities will remain for the development of new HPV vaccines?
- What environmental factors will influence the introduction of novel HPV vaccines?

Key Findings

- New nine-valent HPV vaccines are expected to be widely adopted following market approval, stealing market share from existing vaccines. Though a high price represents a potential barrier to market access.
- Significant environmental barriers to HPV vaccination exist, which currently serve to limit vaccine uptake.
- The emphasis of HPV vaccination is shifting away from an initial focus on cervical cancer prevention in females, towards prevention of a range of cancers in both males and females.
- The inclusion of males in routine HPV vaccine recommendations will expand the size of the HPV vaccines market

Scope

- Overview of the latest advances in prophylactic vaccination.
- Analysis of the future potential for novel and existing HPV vaccines.
- Key topics covered include unmet needs, opportunities, and drivers and barriers specific to prophylactic HPV vaccines.

Reasons to buy

- Understand the dynamics of the prophylactic HPV vaccines market, and the unique barriers to market access.
- Identify opportunities for the development and delivery of HPV vaccines, and to identify emerging players with potentially strong product portfolios.
- Develop business strategies by understanding the trends shaping and driving the future of prophylactic HPV vaccination.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Gain insight on the challenges associated with delivering prophylactic HPV vaccines and the impact of novel...
vaccines.
- Track vaccine sales in the global HPV vaccines market from 2012-2022

Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Vaccination Recommendations and Coverage Rates
4.1 Vaccination Recommendations Overview
4.2 US
4.2.1 Vaccination Recommendations and Policies
4.2.2 Vaccination Coverage
4.2.3 Clinical Practice
4.3 France
4.3.1 Vaccination Recommendations and Policies
4.3.2 Vaccination Coverage
4.3.3 Clinical Practice
4.4 Germany
4.4.1 Vaccination Recommendations and Policies
4.4.2 Vaccination Coverage
4.4.3 Clinical Practice
4.5 Italy
4.5.1 Vaccination Recommendations and Policies
4.5.2 Vaccination Coverage
4.5.3 Clinical Practice
4.6 Spain
4.6.1 Vaccination Recommendations and Policies
4.6.2 Vaccination Coverage
4.6.3 Clinical Practice
4.7 UK
4.7.1 Vaccination Recommendations and Policies
4.7.2 Vaccination Coverage
4.7.3 Clinical Practice
4.8 Japan
4.8.1 Vaccination Recommendations and Policies
4.8.2 Vaccination Coverage
4.8.3 Clinical Practice
4.9 Australia
4.9.1 Vaccination Recommendations and Policies
4.9.2 Vaccination Coverage
4.9.3 Clinical Practice
4.10 Canada
4.10.1 Vaccination Recommendations and Policies
4.10.2 Vaccination Coverage
4.10.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles
5.3.1 Gardasil
5.3.2 Cervarix
6 Unmet Need and Opportunity
6.1 Overview
6.2 Protection against Multiple HPV Types
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Vaccine Coverage Rates
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Perception of Vaccine Safety
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Awareness of HPV Vaccination
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Affordability of HPV Vaccines
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Coverage of HPV Types Prevalent in Certain Populations
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
6.8 Vaccine Compliance Rates
6.8.1 Unmet Need
6.8.2 Gap Analysis
6.8.3 Opportunity
6.9 Lifelong Protection from HPV Infection Not Established
6.9.1 Unmet Need
6.9.2 Gap Analysis
6.9.3 Opportunity
6.10 Ongoing Need for Cervical Cancer Screening
6.10.1 Unmet Need
6.10.2 Gap Analysis
6.10.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
7.2.1 Clinical Trials by Country
7.2.2 Clinical Trials by Phase and Trial Status
7.3 Promising Vaccines in Clinical Development
7.3.1 V503
7.3.2 Xiamen Innovax (Bivalent Vaccine)
7.4 Innovative HPV Vaccines in Early Development
7.4.1 Low-Cost HPV Vaccines
7.4.2 Universal HPV Vaccines
8 Current and Future Players
8.1 Overview
8.2 Trends in Corporate Strategy
8.3 Company Profiles
8.3.1 Merck
8.3.2 GSK
9 Market Outlook
9.1 Global Markets
9.1.1 Forecast
9.1.2 Drivers and Barriers - Global Issues
9.2 US
9.2.1 Forecast
9.2.2 Key Events
9.2.3 Drivers and Barriers
9.3 France
9.3.1 Forecast
Table 12: Gardasil SWOT Analysis, 2014
Table 13: Global Sales Forecasts ($m) for Gardasil, 2012-2022
Table 14: Product Profile - Cervarix
Table 15: Phase III Efficacy Trials - Cervarix
Table 16: Safety Profile - Cervarix
Table 17: Cervarix SWOT Analysis, 2014
Table 18: Global Sales Forecasts ($m) for Cervarix, 2012-2022
Table 19: Overall Unmet Needs - Current and Future Level of Attainment
Table 20: HPV Vaccines - Clinical Trials by Phase and Status, 2014
Table 21: HPV Vaccines - Phase Pipeline, 2014
Table 22: Product Profile - V503
Table 23: V503 SWOT Analysis, 2013
Table 24: Global Sales Forecasts ($m) for V503, 2012-2022
Table 25: Bivalent Vaccine (Xiamen Innovax) SWOT Analysis, 2014
Table 26: Key Companies in the HPV Vaccine Market, 2014
Table 27: Merck's HPV Vaccine Portfolio Assessment, 2014
Table 28: Merck SWOT Analysis, 2014
Table 29: GSK's HPV Vaccine Portfolio Assessment, 2014
Table 30: GSK SWOT Analysis, 2014
Table 31: Global Sales Forecasts ($m) for HPV Vaccines, 2012-2022
Table 32: Global HPV Vaccine Market - Drivers and Barriers, 2014
Table 33: Sales Forecasts ($m) for HPV Vaccines in the United States, 2012-2022
Table 34: Key Events Impacting Sales for HPV Vaccines in the United States, 2012-2022
Table 35: United States HPV Vaccine Market - Drivers and Barriers, 2014
Table 36: Sales Forecasts ($m) for HPV Vaccines in France, 2012-2022
Table 37: Key Events Impacting Sales for HPV Vaccines in France, 2012-2022
Table 38: France HPV Vaccine Market - Drivers and Barriers, 2014
Table 39: Sales Forecasts ($m) for HPV Vaccines in Germany, 2012-2022
Table 40: Key Events Impacting Sales for HPV Vaccines in Germany, 2014
Table 41: Germany HPV Vaccine Market - Drivers and Barriers, 2014
Table 42: Sales Forecasts ($m) for HPV Vaccines in Italy, 2012-2022
Table 43: Key Events Impacting Sales for HPV Vaccines in Italy, 2014
Table 44: Italy HPV Vaccine Market - Drivers and Barriers, 2014
Table 45: Sales Forecasts ($m) for HPV Vaccines in Spain, 2012-2022
Table 46: Key Events Impacting Sales for HPV Vaccines in Spain, 2012-2022
Table 47: Spain HPV Vaccine Market - Drivers and Barriers, 2014
Table 48: Sales Forecasts ($) for HPV Vaccines in the United Kingdom, 2012-2022
Table 49: Key Events Impacting Sales for HPV Vaccines in the United Kingdom, 2012-2022
Table 50: United Kingdom HPV Vaccine Market - Drivers and Barriers, 2014
Table 51: Sales Forecasts ($) for HPV Vaccines in Japan, 2012-2022
Table 52: Key Events Impacting Sales for HPV Vaccines in Japan, 2012-2022
Table 53: Japan HPV Vaccine Market - Drivers and Barriers, 2014
Table 54: Sales Forecasts ($) for HPV Vaccines in Australia, 2012-2022
Table 55: Key Events Impacting Sales for HPV Vaccines in Australia, 2012-2022
Table 56: Australia HPV Vaccine Market - Drivers and Barriers, 2013
Table 57: Sales Forecasts ($) for HPV Vaccines in Canada, 2012-2022
Table 58: Key Events Impacting Sales for HPV Vaccines in Canada, 2012-2022
Table 59: Canada HPV Vaccine Market - Drivers and Barriers, 2014
Table 60: Key Launch Dates
Table 61: Key Patent Expiries
Table 62: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Historical and Projected HPV Vaccination Coverage (%) in the United States among 12-Year-Old Females, 2007-2022
Figure 2: Historical and Projected HPV Vaccination Coverage (%) in France among 14-Year-Old Females, 2007-2022
Figure 3: Historical and Projected HPV Vaccination Coverage (%) in Germany among 17-Year-Old Females, 2009-2022
Figure 4: Historical and Projected HPV Vaccination Coverage (%) in Italy among 12-Year-Old Females, 2009-2022
Figure 5: Historical and Projected HPV Vaccination Coverage (%) in Spain among 14-Year-Old Females, 2008-2022
Figure 6: Historical and Projected HPV Vaccination Coverage (%) in the United Kingdom among 12-Year-Old Females, 2008-2022
Figure 7: Historical and Projected HPV Vaccination Coverage (%) in Japan among 16-Year-Old Females, 2012-2022
Figure 8: Historical and Projected HPV Vaccination Coverage (%) in Australia among 13-Year-Old Females, 2007-2022
Figure 9: Historical and Projected HPV Vaccination Coverage (%) in Canada among 12-Year-Old Females, 2007-2022
Figure 10: HPV Vaccines - Clinical Trials by Country, 2014
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022
Figure 12: Company Portfolio Gap Analysis in HPV Vaccines, 2012-2022
Figure 13: Global Sales for HPV Vaccines by Region, 2012-2022
Figure 14: Sales for HPV Vaccines in the US by Vaccine Class, 2012-2022
Figure 15: Sales for HPV Vaccines in France by Vaccine Class, 2012-2022
Figure 16: Sales for HPV Vaccines in Germany by Vaccine Class, 2012-2022
Figure 17: Sales for HPV Vaccines in Italy by Vaccine Class, 2012-2022
Figure 18: Sales for HPV Vaccines in Spain by Vaccine Class, 2012-2022
Figure 19: Sales for HPV Vaccines in the United Kingdom by Vaccine Class, 2012-2022
Figure 20: Sales for HPV Vaccines in Japan by Vaccine Class, 2012-2022
Figure 21: Sales for HPV Vaccines in Australia by Vaccine Class, 2012-2022
Figure 22: Sales for HPV Vaccines in Canada by Vaccine Class, 2012-2022

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2870448/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2870448/
Office Code: SC6I6YR1

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 10995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 21990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 32985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World